SAN FRANCISCO, Aug. 29, 2016 /PRNewswire/ -- Symic, a clinical stage biotherapeutics company developing therapies inspiredby naturally occurring molecules of the extracellular matrix, today announced that Ken Horne, Chief Executive Officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference.
Time: 11:30 a.m. EDT
Location: Millennium Broadway Hotel, New York
Symic Bio is a clinical stage biotherapeutics company developing therapies inspired by proteoglycans, naturally occurring macromolecules of the extracellular matrix (ECM). The structural and regulatory properties of proteoglycans have potential applications in a wide variety of disease states. Symic Bio currently has two clinical candidates, one to address complications of vascular injury and one for disease modification in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis and oncology.
For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio/ or follow on Twitter at www.twitter.com/symicbio.
David Schull or Rich AllanRusso Partners, LLC(212) 845-4271(646) email@example.com firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/symic-to-present-at-the-23rd-annual-biocentury-newsmakers-in-the-biotech-industry-conference-300319299.html
Subscribe to our Free Newsletters!
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...
Video-electroencephalography monitoring is a diagnostic technique that records the electrical ...
Myomectomy is a surgery that is done to remove fibroids, which are non-cancerous growths of the ...View All